1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

CETP Gets Another Go: NewAmsterdam Phase III Trial Shows Safety And Efficacy

 
• By Jessica Merrill

The first Phase III trial testing the oral CETP inhibitor obicetrapib for the treatment of high cholesterol read out positively, years after some other drugs in the class failed.  

Obicetrapib showed a benefit on LDL-C reduction in patients with HeFH • Source: Shutterstock

The first of four Phase III clinical trials testing NewAmsterdam Pharma BV’s cholesteryl ester transfer protein (CETP) inhibitor obicetrapib for the treatment of high cholesterol has read out positively, teeing the class of drugs up for another shot at the market.

Key Takeaways 
  • NewAmsterdam’s obicetrapib showed statistically significant declines in LDL-C in topline results of the BROOKLYN clinical trial in patients with heterozygous familial hypercholesterolemia (HeFH).
  • CEO Michael Davidson talked to Scrip about the results and the commercial opportunity in the cholesterol market

The company announced topline results of the BROOKLYN clinical trial on 29 July in patients with heterozygous familial hypercholesterolemia (HeFH) whose LDL cholesterol is inadequately

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Merck & Co. CMO Eliav Barr Assures On Pipeline As Keytruda LOE Looms Large

 
• By Jessica Merrill

Chief medical officer Eliav Barr, responsible for overseeing clinical development, talked to Scrip in an interview at Merck’s headquarters about the company’s pipeline diversification.

CNS, Cardiometabolics A Bright Spot In Recent Chinese VC/PE Fundings

 
• By Dexter Jie Yan

Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.